click on circles to display study description...
pembrolizumab plus lenvatinib (n=-9) vs. lenvatinib (n=-9)
randomized controlled trial
lenvatinib in combination with pembrolizumab
Lenvatinib
mHCC - 1st line (L1)
study Misses Primary End Points
powered by vis.js Network